

Cellular Therapies in non-malignant Hematology

Preliminary Programme

Genova, Italy 11-13 September 2024

Wednesday, 11 September 2024

14:00 - 18:00 Severe Aplastic Anaemia Working Party & Haemoglobinopathies Working Party Scientific Business Meetings
Open for everybody

Thursday, 12 September 2024

	inursday, 12 Septer
09:00 - 10:30	Session I: Update on diagnosis, pathophysiology, and clinical presentation of hemoglobinopathies
09:00 - 09:10	Welcome and Introduction
09:10 - 09:30	TDT medical care: today's outcome in different parts of the world and unmet medical need + Q&A
09:30 - 09:50	SCD medical care: today's outcome in different parts of the world and unmet medical need + Q&A
09:50 - 10:10	Work-up for HCT and gene therapy in hemoglobinopathies + Q&A
10:10 - 10:30	Patient and family counseling for HCT and GT (peds and adults) + Q&A
10:30 - 11:00	Coffee Break
11:00 - 11:45	Industry Symposium
11:45 - 13:05	Session II: Update on diagnosis, pathophysiology, natural history, and treatment of bone marrow failure syndromes: listening to the dinosaurs
11:45 - 12:05	50 years of AA: how treatment outcomes have evolved + Q&A
12:05 - 12:25	Changing 'face' of BMF in Children + Q&A
12:25 - 12:45	Long-term outcome of AA patients + Q&A
12:45 - 13:05	Round table: treatment decision in SAA + Q&A
13:05 - 13:45	Lunch Break
13:45 - 14:30	Industry Symposium
14:30 - 15:40	Session III: Transplantation for hemoglobinopathies and bone marrow failure syndromes
14:30 - 14:50	Transplantation for TDT: where we are now + Q&A
14:50 - 15:10	Transplantation for SCD: where we are now + Q&A
15:10 - 15:20	Transplantation for acquired SAA + Q&A
15:20 - 15:40	Transplantation in inherited BMF (role of alternate donors, first line MUD
	in young adults, refractory to IST- is there an age limit?) + Q&A
15:40 - 16:10	Coffee Break



Cellular Therapies in non-malignant Hematology

Genova, Italy 11-13 September 2024

16:10 - 18:10	Session IV: Debate non-transplant treatments for AA and PNH
16:10 - 16:30	Overview
16:30 - 16:50	Triple therapy for AA: updated results (EPAG in children)
16:50 - 17:10	Treatment of AA in Elderly + Q&A
17:10 - 17:30	Treatment for moderate AA: when, why, and how (definition and
	treatment options)+ Q&A
17:30 - 17:50	Treatment of PNH: an update (anti-C + HSCT) + Q&A
17:50 - 18:10	Eltrombopag (and Cyclosporin) 'dependence' (definition of relapse) + Q&A

Friday, 13 September 2024

08:00 - 09:2 T p0	Session V: Innovative cell therapies: Gene therapy, induced pluripotent stem cells, and CAR-T		
	Chairs:		
08:00 - 08:20	Gene therapy status of art in Haemoglobinopathies + Q&A		
08:20 - 08:40	Innovation in Gene therapy + Q&A		
08:40 - 09:00	Gene editing therapy for hemoglobinopathies: lessons learned from the		
	clinical trials that can be translated to future real-world use + Q&A		

Round table on gene therapy today: availability, costs, and priority criteria

09:20 - 09:50	Coffee	Break
---------------	--------	-------

09:00 - 09:20

09:50 -	10.35	Industry	S	ymposium
03.30	10.55	muustiy	_	yiiiposiuiii

10:35 - 12:35 Session VI: Hot topics: the unknowns

10:35 - 10:55	Overview
10:55 - 11:15	Mutations in AA- Transplant or not? Is it MDS or AA? How often do you
	monitor? Frequency of marrow assessment? + Q&A
11:15 - 11:35	Clonal dynamics of hematopoiesis after HSCT & Gene Therapy + Q&A
11:35 - 11:55	Role of Upfront Haplo- Is this the 'new' standard in AA? + Q&A
11:55 - 12:15	How to manage and monitor chimerism in TDT/SCD? + Q&A
12:15 - 12:35	How to manage and monitor chimerism in AA? Role of mixed chimerism
	(including poor graft function and graft failure) + Q&A

12:35 - 13:15 Lunch Break



Cellular Therapies in non-malignant Hematology

Genova, Italy 11-13 September 2024

13:15 - 15:35	Session VII: Status of art in emerging geographic areas, and special topics in cell therapies for non-malignant hematology
13:15 - 13:35	New understanding of iron-related toxicity & Iron toxicity and the hemopoietic
	stem cell (AA and hemoglobinopathies) + Q&A
13:35 - 13:55	Late effects after HSCT for TCD/SCD + Q&A
13:55 - 14:15	Biology of Fanconi anaemia + Q&A
14:15 - 14:35	Update on telomeropathies + Q&A
14:35 - 14:55	New entities in acquired BMF + Q&A
14:55 - 15:15	Fertility in patients transplanted for AA and hemoglobinopathies + Q&A
15:15 - 15:35	Luspatercept and ESA for hemoglobinopathies + Q&A
15:35 - 15:55	Transplantation outside the US and UE
15:55 - 16:00	Take home messages & conclusions